Principal Financial Group Inc. Lowers Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Principal Financial Group Inc. lowered its holdings in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 5.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 101,906 shares of the medical instruments supplier's stock after selling 5,438 shares during the quarter. Principal Financial Group Inc. owned 0.42% of ICU Medical worth $12,101,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. M&T Bank Corp boosted its holdings in ICU Medical by 5.9% during the fourth quarter. M&T Bank Corp now owns 4,938 shares of the medical instruments supplier's stock worth $493,000 after buying an additional 277 shares in the last quarter. Maryland State Retirement & Pension System purchased a new stake in ICU Medical during the fourth quarter worth $890,000. Charles Schwab Investment Management Inc. boosted its holdings in ICU Medical by 14.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 192,773 shares of the medical instruments supplier's stock worth $19,227,000 after buying an additional 23,816 shares in the last quarter. Jump Financial LLC purchased a new stake in ICU Medical during the fourth quarter worth $352,000. Finally, Dimensional Fund Advisors LP lifted its holdings in ICU Medical by 4.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 220,624 shares of the medical instruments supplier's stock valued at $22,005,000 after purchasing an additional 9,196 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company's stock.

ICU Medical Price Performance

Shares of NASDAQ:ICUI traded up $1.13 during midday trading on Friday, hitting $162.32. The company's stock had a trading volume of 268,776 shares, compared to its average volume of 277,349. The business's 50 day simple moving average is $139.10 and its 200 day simple moving average is $116.71. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. The company has a market cap of $3.96 billion, a P/E ratio of -66.25 and a beta of 0.65. ICU Medical, Inc. has a 12-month low of $78.28 and a 12-month high of $166.46.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.56. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The firm had revenue of $596.50 million during the quarter, compared to analysts' expectations of $556.64 million. During the same period last year, the business earned $1.58 earnings per share. ICU Medical's revenue was up 8.6% compared to the same quarter last year. On average, analysts forecast that ICU Medical, Inc. will post 3.76 EPS for the current year.

Insider Buying and Selling

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at $16,320,691.72. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,050 shares of ICU Medical stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $144.11, for a total transaction of $295,425.50. Following the completion of the sale, the vice president now directly owns 4,482 shares in the company, valued at $645,901.02. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the sale, the chief executive officer now owns 104,593 shares of the company's stock, valued at $16,320,691.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,552 shares of company stock worth $4,537,802. Insiders own 6.70% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Raymond James increased their price objective on shares of ICU Medical from $135.00 to $158.00 and gave the company an "outperform" rating in a report on Thursday, August 8th. Needham & Company LLC reissued a "hold" rating on shares of ICU Medical in a research note on Thursday, August 8th. Finally, KeyCorp raised their price target on shares of ICU Medical from $136.00 to $147.00 and gave the stock an "overweight" rating in a research note on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, ICU Medical presently has an average rating of "Moderate Buy" and an average price target of $138.33.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.